Philadelphia Allergy Experts Share Evidence-Based Seasonal Relief
Philadelphia, Pennsylvania | December 30, 2025 —Penn Medicine Becker ENT & Allergy, a leading specialty practice in ear, nose,...
Immunotherapy
Advertisement
FDA Clears Aqualung’s Phase 2a Study in Lung Fibrosis
December 22, 2025 | Juno Beach, Florida — Aqualung Therapeutics announced that the U.S. Food and Drug Administration (FDA)...
LOQTORZI + Chemo Nearly Doubles Survival in NPC at Six Years
REDWOOD CITY, Calif., December 8, 2025 — Coherus Oncology today announced compelling six-year overall survival (OS) follow-up data from...
Columvi Combo Doubles Survival in Three-Year STARGLO Results
Basel, 8 December 2025 — Roche has reported three-year follow-up findings from the pivotal phase III STARGLO study, demonstrating...
OS Therapies Gains Key FDA & EMA Milestones for OST-HER2 Immunotherapy
NEW YORK, NY — December 5, 2025 — OS Therapies Inc. announced two major regulatory milestones advancing its lead...
Advertisements
BriaCell Reveals New Phase 2 and Phase 3 Data Ahead of SABCS 2025
Philadelphia, PA and Vancouver, BC — December 2, 2025 — BriaCell Therapeutics Corp. announced plans to present three major...
Innovent’s PECONDLE Gains NMPA Approval as China’s First IL-23p19 Antibody
SAN FRANCISCO & SUZHOU, China — November 28, 2025. Innovent Biologics has announced that PECONDLE® (picankibart injection), a recombinant...
Junshi Biosciences Phase 3 Trial Confirms JS001sc Success in NSCLC
SHANGHAI, China, Nov. 25, 2025 — Junshi Biosciences announced that its Phase 3 clinical study evaluating JS001sc, a subcutaneous...
Enlivex Reports Strong 6-Month Data for Allocetra in Knee Osteoarthritis
Nes-Ziona, Israel — Nov. 24, 2025 — Enlivex Therapeutics Ltd. announced positive six-month topline results from the Phase IIa...
FDA Clears New KEYTRUDA Regimens for Bladder Cancer Care
Rahway, N.J., Nov. 21, 2025 — In a major advancement for oncology treatment, the U.S. Food and Drug Administration...
Advertisement
